Analysis of resistance-associated substitutions in hepatitis C virus sequences from Kyrgyzstan
- Authors: Kartashov M.Y.1, Svirin K.A.1, Bekbolotov A.A.2, Momusheva K.T.2, Iskanova B.M.2, Solpueva A.S.2, Motorov U.T.3, Narmatova E.B.3, Krivosheina E.I.1, Gladysheva A.V.1, Chub E.V.1, Gashnikova N.M.1
-
Affiliations:
- State Research Center of Virology and Biotechnology “Vector” of Rospotrebnadzor
- Republican Center of AIDS of Ministry of Health of Kyrgyzstan
- Osh Regional Center of AIDS Treatment and Prevention
- Issue: Vol 68, No 3 (2023)
- Pages: 265-270
- Section: SHORT COMMUNICATION
- URL: https://journals.rcsi.science/0507-4088/article/view/132638
- DOI: https://doi.org/10.36233/0507-4088-176
- EDN: https://elibrary.ru/ryhyaa
- ID: 132638
Cite item
Full Text
Abstract
Introduction. The countries of Central Asia, including Kyrgyzstan, are characterized by high prevalence and morbidity of HCV infection. Identification of HCV genotype and mutations associated with resistance to direct-acting antiviral (DAA) plays an important role either in conducting molecular epidemiological studies or choosing the treatment tactics.
The aim of the work was to research of the genotype diversity of HCV variants circulating in Kyrgyzstan and the identification among them the mutations associated with the development of resistance to DAA.
Materials and methods. 38 serum samples from HCV-infected residents of Kyrgyzstan were analyzed in this study. The nucleotide sequences of viral gene fragments (NS3, NS5A, NS5B) were determined by Sanger’s sequencing and deposited in the international GenBank database under the numbers ON841497–ON841534 (NS5B), ON841535–ON841566 (NS5A), and ON841567–ON841584 (NS3).
Results. The HCV subtypes 1b (52.6%; 95% CI 37.3–67.5%), 3a (44.8%; 95% CI 30.2–60.2%) and 1a (2.6%; 95% CI 0.5–13.4%) are circulating in Kyrgyzstan. 37% (95% CI 19–59%) of subtype 1b isolates had C316N mutation in the NS5A gene; 46% (95% CI 23–70%) had F37L mutation in the NS5A gene; 45% (95% CI 22–72%) had Y56F mutation in the NS3 gene. Among subtype 3a isolates, resistance-associated mutations in NS5B fragment were not found. 22% (95% CI 9–45%) of subtype 3a sequences had a Y93H mutation in the NS5A gene. A combination of Y56F + Q168 + I170 mutations was identified among all sequences of NS3 gene. DAA resistance mutations were not found in NS3, NS5A, NS5B genes of subtype 1a sequence.
Conclusion. A rather high prevalence of mutations associated with resistance or significant decrease in sensitivity to DAA among HCV sequences from Kyrgyzstan was shown. Updating of data on HCV genetic diversity is necessary for timely planning of measures to combat epidemic.
Full Text
##article.viewOnOriginalSite##About the authors
Mikhail Yu. Kartashov
State Research Center of Virology and Biotechnology “Vector” of Rospotrebnadzor
Author for correspondence.
Email: mikkartash@yandex.ru
ORCID iD: 0000-0002-7857-6822
PhD (Biology), Senior Researcher, Department of molecular virology
Russian Federation, 630559, Koltsovo, Novosibirsk RegionKirill A. Svirin
State Research Center of Virology and Biotechnology “Vector” of Rospotrebnadzor
Email: svirin_ka@vector.nsc.ru
ORCID iD: 0000-0001-9083-1649
Junior Researcher, Department of molecular virology
Russian Federation, 630559, Koltsovo, Novosibirsk RegionAjbek A. Bekbolotov
Republican Center of AIDS of Ministry of Health of Kyrgyzstan
Email: aibek_0001@mail.ru
ORCID iD: 0000-0001-9931-3311
Deputy Director
Kyrgyzstan, BishkekKunduz T. Momusheva
Republican Center of AIDS of Ministry of Health of Kyrgyzstan
Email: m_kunduza@mail.ru
ORCID iD: 0009-0000-6524-3386
Head of department
Kyrgyzstan, BishkekBaarinisa M. Iskanova
Republican Center of AIDS of Ministry of Health of Kyrgyzstan
Email: baarinisaiskanova@gmail.com
ORCID iD: 0000-0002-2493-1788
Doctor-laborator
Kyrgyzstan, BishkekAjgul' S. Solpueva
Republican Center of AIDS of Ministry of Health of Kyrgyzstan
Email: solpuevaigul@mail.ru
ORCID iD: 0000-0002-1502-9207
Head of department
Kyrgyzstan, BishkekUlukbek T. Motorov
Osh Regional Center of AIDS Treatment and Prevention
Email: umotorov@mail.ru
ORCID iD: 0009-0000-4534-338X
Head of department
Kyrgyzstan, OshEl'mira B. Narmatova
Osh Regional Center of AIDS Treatment and Prevention
Email: elmira.narmatova@yandex.ru
ORCID iD: 0000-0001-9263-0525
PhD (Med.), Assistant Professor, General Head
Russian Federation, OshEkaterina I. Krivosheina
State Research Center of Virology and Biotechnology “Vector” of Rospotrebnadzor
Email: katr962@mail.ru
ORCID iD: 0000-0001-5181-0415
Researcher, Department of molecular virology
Russian Federation, 630559, Koltsovo, Novosibirsk RegionAnastasiya V. Gladysheva
State Research Center of Virology and Biotechnology “Vector” of Rospotrebnadzor
Email: gladysheva_av@vector.nsc.ru
ORCID iD: 0000-0002-7396-3954
PhD (Biology), Senior Researcher, Department of molecular virology
Russian Federation, 630559, Koltsovo, Novosibirsk RegionElena V. Chub
State Research Center of Virology and Biotechnology “Vector” of Rospotrebnadzor
Email: chub_ev@vector.nsc.ru
ORCID iD: 0000-0003-1521-897X
PhD (Biology), Head of department
Russian Federation, 630559, Koltsovo, Novosibirsk RegionNatal'ya M. Gashnikova
State Research Center of Virology and Biotechnology “Vector” of Rospotrebnadzor
Email: ngash@vector.nsc.ru
ORCID iD: 0000-0002-0891-0880
PhD (Biology), Head of department
Russian Federation, 630559, Koltsovo, Novosibirsk RegionReferences
- Baimakhanov Z. Liver transplantation in Kazakhstan: current status and outcomes. In: The 2017 Joint Conference of the ILTS, ELITA, & LICAGE. Prague; 2017. https://doi.org/10.26226/morressier.58eb975ed462b80290b4f9c5
- Rosenkranz M., Kerimi N., Takenova M., Impinen A., Mamyrov M., Degkwitz P., et al. Assessment of health services for people who use drugs in Central Asia: Findings of a quantitative survey in Kazakhstan and Kyrgyzstan. Harm Reduct. J. 2016; 13: 3. https://doi.org/10.1186/s12954-016-0093-2
- Dietz J., Susser S., Vermehren J., Peiffer K.H., Grammatikos G., Berger A., et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology. 2018; 154(4): 976–88.e4. https://doi.org/10.1053/j.gastro.2017.11.007
- Wang G.P., Terrault N., Reeves J.D., Liu L., Li E., Zhao L., et al. Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci. Rep. 2018; 8(1): 3199. https://doi.org/10.1038/s41598-018-21303-2
- Kartashov M.Yu., Svirin K.A., Krivosheina E., Chub E.V., Ternovoy V.A., Kochneva G.V. Prevalence and molecular genetic characteristics of parenteral hepatitis B, C and D viruses in HIV positive persons in the Novosibirsk region. Voprosy virusologii. 2022; 67(5): 423–38. https://doi.org/10.36233/0507-4088-133 https://elibrary.ru/wldbqc (in Russian)
- Palladino C., Ezeonwumelu I.J., Marcelino R., Briz V., Moranguinho I., Serejo F., et al. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci. Rep. 2018; 8(1): 12266. https://doi.org/10.1038/s41598-018-30528-0
- Marascio N., Costantino A., Taffon S., Lo Presti A., Equestre M., Bruni R., et al. Phylogenetic and molecular analyses of more prevalent HCV1b subtype in the Calabria Region, Southern Italy. J. Clin. Med. 2021; 10(8): 1655. https://doi.org/10.3390/jcm10081655
- Chen H., Liu J., Kang Q., Luo H., Tan N., Pan J., et al. Resistant-associated substitutions do not affect HCV RNA and HCV core antigen clearance during direct-acting antiviral agent treatment in a real-world setting. Infect. Drug Resist. 2022; 15: 3373–80. https://doi.org/10.2147/idr.s352873
- Mawatari S., Oda K., Tabu K., Ijuin S., Kumagai K., Inada Y., et al. New resistance – associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir. J. Gastroenterol. 2017; 52(7): 855–67. https://doi.org/10.1007/s00535-016-1303-0
- Komatsu T.E., Boyed S., Sherwat A., Tracy L., Naeger L.K., O’Rear J.J., et al. Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology. 2017; 152(3): 586–97. https://doi.org/10.1053/j.gastro.2016.10.017
- Wang C., Valera L., Jia L., Kirk M.J., Gao M., Fridell R.A. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob. Agents Chemother. 2013; 57(1): 611–3. https://doi.org/10.1128/aac.01874-12
- Ng T.I., Krishnan P., Pilot-Matias T., Kati W., Schnell G., Beyer J., et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob. Agents Chemother. 2017; 61(5): e02558-16. https://doi.org/10.1128/aac.02558-16
- Gane E.J., Shiffman M.L., Etzkorn K., Morelli G., Stedman C.A.M., Davis M.N., et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology. 2017; 66(4): 1083–9. https://doi.org/10.1002/hep.29256
- Gottwein J.M., Pham L.V., Mikkelsen L.S., Ghanem L., Ramirez S., Scheel T.K.H., et al. Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1–7 and escape variants. Gastroenterology. 2018; 154(5): 1435–48. https://doi.org/10.1053/j.gastro.2017.12.015
- Krishnan P., Beyer J., Mistry N., Koev G., Reisch T., DeGoey D., et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob. Agents Chemother. 2015; 59(2): 979–87. https://doi.org/10.1128/aac.04226-14
- Hernandez D., Zhou N., Ueland J., Monikowski A., McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J. Clin. Virol. 2013; 57(1): 13–8. https://doi.org/10.1016/j.jcv.2012.12.020